XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.19.2

Revenues (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2019
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Three months ended June 30,
|  | 2019 |  | 2018
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
Enbrel® (etanercept) |  | $ | 1,315 |  |  | $ | 48 |  |  | $ | 1,363 |  |  | $ | 1,252 |  |  | $ | 50 |  |  | $ | 1,302 |
Neulasta® (pegfilgrastim) |  | 719 |  |  | 105 |  |  | 824 |  |  | 948 |  |  | 152 |  |  | 1,100 |
Prolia® (denosumab) |  | 458 |  |  | 240 |  |  | 698 |  |  | 396 |  |  | 214 |  |  | 610 |
XGEVA® (denosumab) |  | 379 |  |  | 120 |  |  | 499 |  |  | 339 |  |  | 113 |  |  | 452 |
Aranesp® (darbepoetin alfa) |  | 192 |  |  | 244 |  |  | 436 |  |  | 241 |  |  | 231 |  |  | 472 |
KYPROLIS® (carfilzomib) |  | 166 |  |  | 101 |  |  | 267 |  |  | 151 |  |  | 112 |  |  | 263 |
EPOGEN® (epoetin alfa) |  | 223 |  |  | — |  |  | 223 |  |  | 250 |  |  | — |  |  | 250 |
Sensipar®/Mimpara® (cinacalcet) |  | 43 |  |  | 79 |  |  | 122 |  |  | 330 |  |  | 90 |  |  | 420 |
Other products |  | 647 |  |  | 495 |  |  | 1,142 |  |  | 460 |  |  | 350 |  |  | 810 |
Total product sales(1) |  | $ | 4,142 |  |  | $ | 1,432 |  |  | 5,574 |  |  | $ | 4,367 |  |  | $ | 1,312 |  |  | 5,679 |
Other revenues |  |  |  |  |  | 297 |  |  |  |  |  |  | 380 |
Total revenues |  |  |  |  |  | $ | 5,871 |  |  |  |  |  |  | $ | 6,059 |
|  | Six months ended June 30,
|  | 2019 |  | 2018
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
ENBREL |  | $ | 2,421 |  |  | $ | 93 |  |  | $ | 2,514 |  |  | $ | 2,302 |  |  | $ | 105 |  |  | $ | 2,407 |
Neulasta® |  | 1,612 |  |  | 233 |  |  | 1,845 |  |  | 1,957 |  |  | 298 |  |  | 2,255 |
Prolia® |  | 848 |  |  | 442 |  |  | 1,290 |  |  | 716 |  |  | 388 |  |  | 1,104 |
XGEVA® |  | 735 |  |  | 235 |  |  | 970 |  |  | 671 |  |  | 226 |  |  | 897 |
Aranesp® |  | 374 |  |  | 476 |  |  | 850 |  |  | 466 |  |  | 460 |  |  | 926 |
KYPROLIS® |  | 320 |  |  | 192 |  |  | 512 |  |  | 288 |  |  | 197 |  |  | 485 |
EPOGEN® |  | 442 |  |  | — |  |  | 442 |  |  | 494 |  |  | — |  |  | 494 |
Sensipar®/Mimpara® |  | 178 |  |  | 157 |  |  | 335 |  |  | 739 |  |  | 178 |  |  | 917 |
Other products |  | 1,203 |  |  | 899 |  |  | 2,102 |  |  | 881 |  |  | 656 |  |  | 1,537 |
Total product sales(1) |  | $ | 8,133 |  |  | $ | 2,727 |  |  | 10,860 |  |  | $ | 8,514 |  |  | $ | 2,508 |  |  | 11,022 |
Other revenues |  |  |  |  |  | 568 |  |  |  |  |  |  | 591 |
Total revenues |  |  |  |  |  | $ | 11,428 |  |  |  |  |  |  | $ | 11,613 |
____________ (1) Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2019 and 2018.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration